Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Cellular Biomedicine Expands into Arthritis Market | Contract Pharma

What are you searching for?

Sign in
Breaking News

Cellular Biomedicine Expands into Arthritis Market

Gets IP go-ahead for Chinese market

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Cellular Biomedicine Group, a biopharma firm engaged in the development of treatments for degenerative and cancerous diseases, plans to expand into the China Osteoarthritis and Rheumatoid Arthritis market. Following a complete analysis of current China patents by an intellectual property law firm, Cellular Biomedicine Group has clearance to pursue IP operation with respect to its patents for autologous and allogeneic adipose-derived stem cell compositions for the treatment of osteoarthritis and rheumatoid arthritis, as well as for various stem cell processing and preservation technologies.
 
Dr. Wei (William) Cao, president of Cellular Biomedicine Group, said, “In China there are 72.5 million people suffering from knee osteoarthritis (KOA), and 4.5 million suffering from rheumatoid arthritis (RA). We are very confident to enter the world’s largest KOA and RA market with freedom of operation.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics